ACRS News and Press, Aclaris Therapeutics Inc.

WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief E...

2026-05-14 14:30:46 ET Aclaris Therapeutics, Inc. (ACRS) Bank of America Global Healthcare Conference 2026 May 14, 2026 12:35 PM EDT... Read the full article on Seeking Alpha For further details see: Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Health...

WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris’ Preside...

2026-05-07 07:01:32 ET More on Aclaris Therapeutics Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates - Slideshow Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bi...

- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual Mechanism of ATI-2138 Supports Planned Phase 2b Clinical Trial in Lichen Planus - - St...

2026-05-05 08:15:09 ET Biren Amin from Piper Sandler issued a price target of $11.00 for ACRS on 2026-05-05 10:53:29. The adjusted price target was set to $11.00. At the time of the announcement, ACRS was trading at $4.53. The overall price target consensus is at $10.50 ...

2026-04-28 14:01:56 ET Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates April 28, 2026 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: Aclaris Therapeutics, Inc. (ACRS) Disc...

- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -  - Estimated Half-Life of Approximately 45 Days; Unlocks Op...

WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and ...

WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ C...